DU-145 Docetaxel-Resistant Prostate Cancer Model Service

The DU-145 Docetaxel-Resistant Prostate Cancer Model Service provides a deeply validated in vitro and in vivo system for investigating acquired resistance to docetaxel, the standard-of-care chemotherapeutic agent in advanced prostate cancer. Alfa Cytology offers this model as a complete preclinical solution—stepwise docetaxel selection in adherent DU-145 culture, resistance-index benchmarking against matched parental controls, mechanism-oriented profiling spanning drug transport, microtubule biology, and apoptosis, and optional resistant xenograft cohorts with docetaxel treatment arms in immunodeficient mice—so that clients can advance taxane-resistance and chemosensitizer programs on a well-documented foundation.

Overview of DU-145 Docetaxel-Resistant Prostate Cancer Model

The DU-145 docetaxel-resistant prostate cancer model is derived from DU-145, a human prostate carcinoma cell line established from a central nervous system metastasis of prostate adenocarcinoma. DU-145 is androgen-insensitive, expresses only low levels of androgen receptor, and carries a mutant p53 background—features that make it a standard system for studying aggressive, hormone-refractory disease. Under prolonged, stepwise exposure to docetaxel, surviving subclones acquire markedly reduced drug sensitivity, producing resistant sublines documented in the literature under designations such as DU145R, DU-145DOC10, and DU145-TxR. Reported parental docetaxel IC₅₀ values fall in the low-nanomolar range (roughly 1–3 nM), while induced resistant variants reach approximately 10–130 nM depending on the selection intensity—corresponding to resistance indices of about 3- to 100-fold—and frequently display cross-resistance to paclitaxel, vinblastine, doxorubicin, and estramustine, mirroring the multidrug insensitivity that complicates taxane therapy in the clinic.

Fig 1. ABCB1/P-gp validation and erastin reversal in the DU-145 docetaxel-resistant model: relative ABCB1 mRNA bars (PC-3-P/DU-145-P/PC-3-DR/DU-145-DR), P-gp Westerns with GAPDH across PC3-P/PC3-DR and DU145-P/DU145-DR with erastin dose-titration (0–2.5 μM), ATF3 Western, and Rh-123/vinblastine efflux histogram overlays showing erastin blocking P-gp transport. (Chen, Fangfang, et al., 2024)

Mechanistically, docetaxel resistance in DU-145 is a multi-layered phenotype. Docetaxel kills tumor cells by binding β-tubulin and stabilizing microtubules, forcing prolonged mitotic arrest and apoptosis; resistant cells subvert this mechanism through several documented routes: overexpression of drug-efflux transporters—P-glycoprotein (ABCB1) in particular, whose inhibition by agents such as elacridar or ritonavir partially restores sensitivity—together with MRP1 (ABCC1) and loss of the uptake transporter SLCO1B3; alterations in the drug target itself, including βIII-tubulin (TUBB3) overexpression, microtubule-associated protein tau (MAPT) up-regulation, and β-tubulin mutations that reduce drug-binding affinity; apoptotic reprogramming with Bcl-2/Bcl-xL and survivin elevation; and EMT-like phenotypic drift with cancer stem cell enrichment (CD44 up-regulation, CD24 loss, increased sphere-forming capacity), accompanied by activated Notch/Hedgehog signaling. Because these layers operate simultaneously, the paired parental/resistant DU-145 system—extendable into immunodeficient-mouse xenografts with docetaxel treatment arms—serves as a robust preclinical platform for validating efflux-pump inhibitors, microtubule-targeting next-generation taxanes, and apoptosis-sensitizing combinations.

Principles of DU-145 Docetaxel-Resistant Prostate Cancer Model Construction

Model construction is based on chronic, intermittent selection with a microtubule-stabilizing taxane. Because DU-145 is adherent and relatively sensitive to docetaxel in the low-nanomolar range, exposure begins near the parental IC₅₀ and is raised stepwise over several months: each concentration step applies drug pressure for days to weeks, surviving cells are allowed to regrow to confluence in drug-free recovery phases, and the concentration is then incremented. Cells that survive each escalation—typically those with reinforced efflux pumps, modified microtubule dynamics, or apoptosis evasion—expand until they dominate the culture. The stable phenotype is verified to persist after drug withdrawal before the subline is considered established.

Our Services

With protocols refined through long-term taxane selection programs, Alfa Cytology provides the DU-145 docetaxel-resistant prostate cancer model as a fully documented preclinical asset: clients receive authenticated resistant cell banks with quantified resistance indices, matched parental controls, transport/microtubule/apoptosis profiling, and—where a whole-tumor readout is required—resistant xenograft cohorts with docetaxel treatment arms, all captured in traceable study reports ready for chemosensitizer screening and next-generation taxane evaluation.

Workflow of DU-145 Docetaxel-Resistant Prostate Cancer Model Construction

Construction proceeds as a monitored, multi-month escalation program in which each concentration step is gated by demonstrated regrowth, and each milestone is confirmed with quantitative sensitivity testing against parental controls. Baseline characterization of the parental line precedes selection; phenotypic confirmation precedes molecular profiling; and an optional xenograft stage extends validated resistance into immunodeficient mice. The typical sequence includes the following steps:

1. Parental line qualification and baseline profiling: DU-145 cells are revived, authenticated, and mycoplasma-tested; baseline docetaxel IC₅₀, doubling time, and basal transporter/tubulin expression are documented as reference values.
2. Initiation of docetaxel exposure: Early-passage adherent cells are exposed to a low docetaxel concentration near the parental IC₅₀ (about 0.1–2 nM) with medium refreshed every 2–3 days while morphology and viability are recorded.
3. Stepwise dose escalation: Once cultures demonstrate stable regrowth, the concentration is raised incrementally (by roughly 1–2 nM per cycle) over 3–12 months until cells proliferate robustly at a maintenance level of 10–100 nM.
4. Stabilization and drug-free rest: The resistant pool is passaged continuously under selection pressure, then cultured without docetaxel for one to two weeks to verify that the reduced response is heritable and not residual-drug carryover.
5. In vitro resistance confirmation. Docetaxel dose–response curves are generated by MTT/CCK-8 assay for parental and resistant cells, the resistance index is calculated from IC₅₀ values, and clonogenic and sphere-formation assays confirm long-term fitness.
6. Molecular and phenotypic profiling: Transport readouts (P-gp, MRP1, SLCO1B3 expression and efflux function), microtubule-pathway analysis (TUBB3, MAPT, β-tubulin status), apoptosis markers (Bcl-2, survivin, caspase activity), and EMT/stemness markers (E-cadherin, vimentin, CD44/CD24) map the resistance landscape.
7. Resistant xenograft establishment (optional: in vivo stage). Validated resistant cells are inoculated subcutaneously into immunodeficient mice (typically 5 × 10⁶ cells per site, often with Matrigel), and docetaxel treatment arms (commonly 10–20 mg/kg i.v. weekly) benchmark resistant tumors against parental xenografts.
8. Quality control and release: A release package covering authentication, mycoplasma status, passage history, resistance-index reports, molecular profiling, and xenograft characterization is finalized before the model is delivered for study use.

Fig 2. DU-145 Docetaxel-Resistant Prostate Cancer Model Construction Workflow.

Case Study-DU-145 Docetaxel-Resistant Prostate Cancer Model Development

In a representative preclinical engagement, the Alfa Cytology team generated and characterized a docetaxel-resistant DU-145 subline for a client evaluating efflux-pump inhibition and next-generation taxane strategies. Sustained stepwise selection produced a stable resistant population with a clearly elevated resistance index relative to parental cells, and profiling highlighted transporter-driven drug efflux together with an EMT/stem-like phenotypic shift. The validated subline was applied to combination-treatment screening, and complementary xenograft studies with docetaxel treatment arms contextualized cellular findings at the whole-tumor level. Engagement-specific datasets and study reports from this and similar programs are available upon request under confidentiality.

Why Choose Alfa Cytology?

Alfa Cytology couples meticulous nanomolar-scale selection practice with mechanism-driven characterization, ensuring that every DU-145 docetaxel-resistant model is stable, traceable, and immediately useful for taxane-resistance research. Distinct reasons to work with us include:

• Refined low-nanomolar escalation methodology producing stable, heritable docetaxel resistance.
• Quantitative resistance-index benchmarking against matched parental controls with orthogonal assay confirmation.
• Comprehensive mechanism profiling spanning drug transport, microtubule biology, apoptosis, and stemness.
• Optional in vivo stage featuring resistant xenografts with standard docetaxel treatment arms.
• Full traceability via authentication, mycoplasma screening, passage logs, and milestone-based reporting.
• Confidential, adaptive project management aligned to chemosensitizer and combination-program timelines.

Contact Us

If your prostate cancer research program requires a validated docetaxel-resistant model, we invite you to reach out to us to discuss how the DU-145 docetaxel-resistant prostate cancer model can strengthen your preclinical studies. Contact the Alfa Cytology team today for a customized study plan, timeline, and quotation tailored to your research goals.

For research use only. Not intended for any clinical use.